LONDON, June 18 (Reuters) - Britain’s health cost watchdog has recommended Amgen’s (AMGN.O) new drug Prolia, or denosumab, as a treatment for the brittle bone disease osteoporosis in women who cannot take the older class of bisphosphonate drugs.
LONDON, June 18 (Reuters) - Britain’s health cost watchdog has recommended Amgen’s (AMGN.O) new drug Prolia, or denosumab, as a treatment for the brittle bone disease osteoporosis in women who cannot take the older class of bisphosphonate drugs.
